51results about How to "Helps reflect disease state" patented technology

The invention belongs to the technical field of neoplastic disease diagnosis, and discloses a kit for early diagnosis of neoplastic disease, a method and applications of the kit. The kit includes a specific capturing and detecting system for a tumor exosome and a molecular beacon fluorescent detection system. The specific capturing and detecting system for the tumor exosome includes a solution ofa magnetic gold nanosphere composite modified by a tumor exosome specific ligand and adopting ferric ferrous oxide as a core, and a gold nanocage solution modified by the exosome specific ligand. Themolecular beacon fluorescent detection system includes a molecular beacon probe provided with a fluorescent group, fluorescent amplification substrate hybrid chains provided with fluorescent groups and a buffer liquid. The kit and the method combine tumor exosome specific capturing and analysis and a molecular beacon fluorescent detection method, and greatly increases accuracy and reliability of early diagnosis of tumor.

The invention belongs to the fields of gene engineering and oncology and discloses a serum / plasma miRNA marker associated with breast cancer and application thereof. The marker is a combination of miR-16, miR-25, miR-222 and miR-324-3p. The maker and primers thereof can be used for preparing a diagnosis kit and assisting early diagnosis of the breast cancer.

The invention relates to a kit for a serum / plasma lncRNA marker related to stomach cancer. The serum / plasma lncRNA marker is combination of MALAT1 and HOTAIR, a primer is a primer for the MALAT1 and the HOTAIR, and the upstream primer sequence and the downstream primer sequence of the MALAT1 are SEQ No.1 and SEQ No.2; the upstream primer and the downstream primer of the HOTAIR are SEQ No.3 and SEQ No.4. By means of the kit, the defect that a kit only adopting one serum / plasma lncRNA as the tumor marker is low in sensitivity and specificity, so that the fault diagnosis rate and the rate of early gastric cancer diagnosis are greatly raised is overcome; by means of the kit, the sensitivity and specificity of disease diagnosis are enhanced, successful development of the lncRNA biological marker is beneficial to auxiliary diagnosis of stomach cancer and provides reference for research of biological markers of other diseases, lncRNA chip detection is adopted to obtain a serum / plasma lncRNA expression profile for disease specificity and abnormity expression, a qRT-PCR method is applied to conduct single verification, and dye method is adopted to conduct verification.

The invention belongs to the fields of genetic engineering and oncology, and discloses a blood serum / blood plasma micro ribonucleic acid (miRNA) marker relevant with pancreatic cancer and application thereof. The marker is formed by combining miR-451 and miR-490-3p. The marker and primers of the marker can be used for preparing a diagnostic kit and are used for the auxiliary diagnosis of pancreatic cancer.

The invention belongs to the fields of gene engineering and reproductive medicine, and discloses a single nucleotide polymorphism (SNP) marker related with clinically cryptogenic non-obstructive azoospermia aided diagnosis and application of the SNP marker. The marker is a combination of rs1014331, rs10765875, rs10889203, rs11066453, rs11167809, rs12097821, rs1990264, rs3000811, rs3130048, rs391129, rs4716515, rs658239, rs6589102, rs7042232, rs7099208, rs7144703, rs7194 and rs985421. The marker can be used for preparing a clinically cryptogenic non-obstructive azoospermia aided diagnosis kit.

The invention belongs to the fields of gene engineering and tumor medicine, and discloses an early stomach cancer assisted diagnosis related SNP (single-nucleotide polymorphism) marker and application thereof. The marker is a combination of rs10737808, rs10193016, rs7607715, rs2904350, rs17312167, rs13168609, rs561443, rs7810066, rs10257532, rs3849222, rs11817406, rs7193854, rs12447431 and rs4790224. The marker can be used for preparing an early stomach cancer assisted diagnosis kit.

The invention belongs to the fields of gene engineering and tumor medicines, and discloses an SNP (Single Nucleotide Polymorphism) marker correlated to assistant diagnosis of primary lung cancer and application thereof. The marker is a combination of the following 63 SNP: rs107401, rs465498, rs663414, rs622917, rs636586, rs741061, rs855641, rs948783, rs1544694, rs1663689, rs2030378, rs2225588, rs2317683, rs2395166, rs2405271, rs2788713, rs3130975, rs4344933, rs4488809 and the like. The marker can be used for preparing an assistant diagnosis kit for the primary lung cancer.

The invention discloses a blood miRNA marker related to liver cancer and an application thereof. The marker is the combination of tumor-induced exosome sourced miRNA-26a and miRNA-199a in human blood. According to the invention, tumor-induced exosome in peripheral blood of liver cancer patient and liver benign disease patient can be separated and purified, miRNA of two expression difference can be analyzed and screened by a miRNA chip, and the above conclusion is passed by a QPCR verification. The marker and its detection reagent can be used for preparing a diagnostic kit, which can be used for early diagnosis of liver cancer.

The invention belongs to the fields of gene engineering and tumor medicines, and discloses an SNP (Single Nucleotide Polymorphism) marker correlated to assistant diagnosis of noncardia cancer and application thereof. The marker is a combination of the following 25 SNP: rs1950476, rs238889, rs7973779, rs1445227, rs7528071, rs1549058, rs9841504, rs749130, rs17032274, rs3027247, rs9578831, rs714842, rs17262413, rs16924994, rs13361707, rs12496648, rs2826151, rs12416175, rs3753473, rs7349868, rs60266313 and the like. The marker can be used for preparing an assistant diagnosis kit for the noncardia cancer.

The invention discloses a plasma exosome tRFs marker and an application thereof to breast cancer diagnosis. The marker is an exosome-derived tRF-Ser-AGA-018. The application of the marker includes theoperating steps: A building a unified specimen bank and a database, acquiring blood samples and tissue samples conforming to standards by standard operating procedures, and systematically collectingcomplete clinical data of included crowds; B analyzing tumor-induced exosome-derived tRFs disparity expression spectra in blood, selecting plasma samples of breast cancer cases and healthy persons, breast cancer tissues and para-carcinoma tissues, extracting exosomes, sequencing tRFs and tiRNA and screening out differentially expressed tRFs; C performing QRT-PCR (quantitative reverse transcriptionpolymerase chain reaction) analysis on the screened differentially expressed tRFs in large sample crowds. The tumor-induced exosome tRFs in the blood is a novel biomarker which realizes stability, minimal invasiveness and real-time monitoring, the sensitivity and the specificity of disease diagnosis are greatly improved, and successful development of the non-coding RNA (ribonucleic acid) biomarker is beneficial to breast cancer diagnosis.

The invention relates to a plasma / serum circulation microRNA marker related to mlignnt melnom and application of the marker. The plasma / serum circulation microRNA marker related to mlignnt melnom is combination of miR-610, miR-1224-5p, miR-125a-3p and miR-557. The invention provides the plasma / serum circulation microRNA marker which has the capability of early diagnosis and mlignnt melnom screening and is related to mlignnt melnom, and the application of the marker.

The invention belongs to the field of molecular biology, and discloses a pancreatic cancer-associated serum / plasma tsRNA marker and application thereof. The marker is tRF-Pro-AGG-004 and / or tRF-Leu-CAG-002. The tsRNA screened by the invention has significantly higher specificity and sensitivity for detection of pancreatic cancer patients than protein markers currently used in clinical practice, and greatly improves the accuracy of diagnosis. The marker can be used to prepare a diagnostic kit for auxiliary early diagnosis of pancreatic cancer.

The invention belongs to the medical field of genetic engineering and tumors, and discloses an SNP marker related to auxiliary diagnosis of lung cancer of non-smoking women and applications thereof. The marker is a combination of 25 SNPs such as rs10051970, rs10087140, rs10483845, rs11233751, rs11643408, rs11732247, rs1255485, rs12612657, rs11643408, rs11732247, rs16935064, rs12612657, rs1535271, rs166402, rs16935064, rs12612657, rs1535271, rs166042, rs16935064, 17040797, rs17073021, rs17623941, rs17670695, rs2550911, rs40395, rs4454390 and rs4640379. The marker can be used for preparing a kit for the auxiliary diagnosis of lung cancer of non-smoking women, and applications thereof.

The invention relates to a clinically unexplained NOA (non-obstructive azoospermia)-related mitochondrial DNA SNP (single nucleotide polymorphism) marker and applications thereof, belonging to the fields of genetic engineering and reproductive medicine. The marker is a combination of the following mitochondrial DNA SNP sites: T3394C, A6881G, G11696A, G13135A, G13928C, A15662G, T15968C, T16224C and G16319A. The marker and specific primers and / or specific probes thereof can be used for auxiliary diagnosis of the clinically unexplained NOA, greatly improving the sensitivity and specificity of diagnosis.

The invention belongs to the field of genetic engineering and reproductive medicine and discloses an SNP marker related to auxiliary diagnosis of non-syndromic congenital heart disease and an application thereof. The SNP marker is composed of rs3789612, rs4140836, rs13391263, rs13101737, rs1400558, rs6872396, rs13189951, rs9266596, rs7863990, rs2433752, rs7259736, rs490514, rs2474937, rs1531070, rs9533839, rs17019472, rs10182004, rs9461938, rs72759270 and rs1886441. The marker can be used for preparing an auxiliary diagnosis kit of the non-syndromic congenital heart disease.

The invention belongs to the fields of genetic engineering and oncology, and discloses a serum / plasma miRNA marker for early diagnosis of noncardiac gastric carcinoma and applications thereof. The marker is a composition of miR-16, miR-25, miR-92a, miR-451 and miR-486-5p. The marker and primers thereof can be used for preparing a diagnosis kit, and used for assistant early diagnosis of the noncardiac gastric carcinoma.

The invention belongs to the field of genetic engineering and oncology, and discloses a low-frequency high-penetrance genetic marker associated with the auxiliary diagnosis of primary lung carcinoma and applications of the marker. The marker is a combination of 35 genetic loci such as rs1131897, rs1133833, rs115019901, rs117855259, rs118154190, rs141059768, rs141350740, rs142881943, rs145529151, rs145638335, rs145940981, rs150279473, rs150695913, rs151223396, rs185832840 and rs188159138. The marker can be used for preparing kits for the auxiliary diagnosis of primary lung carcinoma.

The invention discloses a serum exosome tsRNA marker related to breast cancer diagnosis and application thereof, and belongs to the field of molecular biology and oncology. The marker is a combination of tRF-Glu-TTC-009, tRF-Gly-TCC-010 and tRF-His-GTG-005 in a serum exosome tsRNA. The marker has relatively high sensitivity and specificity and is beneficial to auxiliary diagnosis of breast cancer.

The invention discloses a micro-RNA marker and application thereof to preparation of a product for the diagnosis of a chronic thromboembolic pulmonary hypertension CTEPH disease. The micro-RNA markeris hsa-miR-20a-5p. The invention further discloses a kit; the kit contains a reagent for determining the has-miR-20a-5p marker. The kit for chronic thromboembolic pulmonary hypertension CTEPH miRNA disease detection is quick and convenient and can realize the early diagnosis and the prediction of CTEPH.

The invention belongs to the fields of gene engineering and oncology and discloses a serum / plasma miRNA marker associated with breast cancer and application thereof. The marker is a combination of miR-16, miR-25, miR-222 and miR-324-3p. The maker and primers thereof can be used for preparing a diagnosis kit and assisting early diagnosis of the breast cancer.

The invention belongs to the fields of gene engineering and oncology, and discloses a mammary cancer assisted diagnosis related SNP (single-nucleotide polymorphism) marker and application thereof. The marker is a combination of 32 SNPs, such as rs10152591, rs1037699, rs10487075, rs11645106, rs11663688, rs11768670, rs11910707, rs12972670, rs13038095, rs142255517, rs142895740, rs144600021, rs17128116, rs2053026, rs213212, rs2229300, rs2981582, rs35002951, rs3748140 and the like. The marker can be used for preparing a mammary cancer assisted diagnosis kit.

The invention belongs to the field of genetic engineering and tumor medicine, and discloses a cancer-testis genetic marker related to primary lung cancer auxiliary diagnosis and application thereof. The marker is combination of rs12166583, rs12477419, rs75764106, rs74640907, rs74377505, rs1007089, rs1433646, rs6001675, rs11125117, rs3747093 and rs793598. The marker can be used for preparing primary lung cancer auxiliary diagnosis kit, and has a relatively good clinical application prospect.

The invention belongs to the genetic engineering and tumour medicine fields and discloses an SNP marker related to primary hepatocellular carcinoma auxiliary diagnosis and an application of the SNP marker. The marker is a combination of rs7574865, rs1012068, rs17401966, rs2596542, rs455804, rs9272105, rs9275319 and rs9275572. The marker can be used for preparing a hepatic carcinoma auxiliary diagnosis kit.

The invention belongs to the field of genetic engineering and reproductive medicine and discloses a low frequency SNV marker associated with sporadic non-syndromic CHD (congenital heart disease) auxiliary diagnosis and an application of the low frequency SNV marker. The marker is a combination of 41 low frequency SNVs such as rs75423398, rs7527798, rs200531164, rs6756629, rs139026854, rs79043251, rs1801212, rs4956145, rs7689099, rs145248317, rs34525648, rs16891235, rs13194053, rs41269281, rs41270593, rs3130250 and rs3130379. The marker can be used for preparing a sporadic non-syndromic CHD auxiliary diagnosis kit.

The invention belongs to the technical field of biology, and discloses a tsRNA marker for detecting cancer tissue and para-carcinoma tissue of pancreatic cancer, and application thereof in prognosis and survival judgment of pancreatic cancer. The tsRNA marker is tRF-Pro-AGG-004 and / or tRF-Leu-CAG-002. The marker can be used for preparing a kit for monitoring and prognosis evaluation of pancreaticcancer.

The invention belongs to the technical field of oncology medicine, and specifically discloses an SNP marker associated with the auxiliary diagnosis of esophageal cancer. The SNP marker is a combination of rs10052657, rs10058728, rs2014300, rs4072037, rs2239815, rs9288318, rs3763338, rs9868873, rs3781264, rs4822983 and rs8030672. The SNP marker combination can be used for assisting in clinical screening diagnosis of the esophageal cancer, helps to reflect the disease state of asymptomatic high-risk groups suffering from the esophageal cancer, and provides support for clinicians to quickly and accurately know the disease conditions of patients and timely take more personalized prevention and treatment schemes.

The invention belongs to the field of genetic engineering and oncology, and discloses an SNP marker for assisting in diagnosing non-small cell lung cancer and application thereof. The marker is a combination of rs2293607, rs10429489, rs2517873, rs4573350, rs1200399, rs4236709, rs13167280, rs17038564, rs55768116, rs1853837, rs12265047, rs401681, rs77468143, rs11610143, rs35201538 and rs3817963. Themarker can well distinguish healthy controls and non-small cell lung cancer patients, and can be used for preparing a non-small cell lung cancer auxiliary diagnostic kit.

The invention discloses a micro-RNA marker and application thereof to preparation of a product for the diagnosis of a chronic thromboembolic pulmonary hypertension CTEPH disease. The micro-RNA markeris hsa-miR-20a-5p. The invention further discloses a kit; the kit contains a reagent for determining the has-miR-20a-5p marker. The kit for chronic thromboembolic pulmonary hypertension CTEPH miRNA disease detection is quick and convenient and can realize the early diagnosis and the prediction of CTEPH.

The invention discloses a blood miRNA marker related to human liver cancer and an application. The marker is miRNA-26a from exosome. According to the invention, tumor-induced exosome in peripheral blood of liver cancer patient and liver benign disease patient can be separated and purified, miRNA-199a for expressing difference in the liver cancer patient and liver benign disease patient can be analyzed and screened by a miRNA chip, and the liver cancer can be determined for the subjects by detecting miRNA-26a. The marker and its detection reagent can be used for preparing a diagnostic kit and used for early diagnosis of liver cancer.

The invention belongs to the technical field of biology, and particularly relates to a molecular diagnosis technology for adenomyosis. According to the technical scheme, the miRNA kit for diagnosing adenomyosis comprises any combination of reverse transcription primers of hsa-miR-22-3p, hsa-miR-182-5p and hsa-miR-103a-3p, a reagent for a probe method qPCR reaction, namely a probe and forward and reverse PCR primers. The kit can also comprise a single-chain RNA standard substance of the hsa-miR-22-3p, the hsa-miR-182-5p and the hsa-miR-103a-3p. A serum miRNAs expression database and a specific marker, namely any combination of hsa-miR-22-3p, hsa-miR-182-5p and hsa-miR-103a-3p, related to adenomyosis incidence are obtained through a large amount of deep research in the early stage. Then any two of the hsa-miR-22-3p, the hsa-miR-182-5p and the hsa-miR-103a-3p are detected through development and application of the specific diagnostic kit. As a diagnostic specificity index, the diagnosis of adenomyosis can be more convenient and easy to implement.